Drug Trial Radar · NCT06307795
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Jun 24, 2024
Primary completion
Apr 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Avistone Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Conditions
- Locally Advanced or Metastatic Solid Tumors
Interventions
ANS014004Drug
Varying doses of ANS014004
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From the time of first dose to 28 days post last dose of ANS014004
- Incidence of Serious Adverse Events (SAEs)Time frame: From time of first dose to 28 days post last dose of ANS014004
- Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: From time of first dose of ANS014004 to end of DLT period (approximately 30 days)
- Incidence of baseline laboratory finding, ECG and vital signs changesTime frame: From time of first dose to 28 days post last dose of ANS014004
- Proportion of patients with radiological response (ORR)Time frame: From date of first dose of ANS014004 until progression, or the last evaluable assessment in the absence of progression (approximately 2 years))
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
University of California, San Diego
San Diego, California · Recruiting
Sarah Cannon Research Institute
Denver, Colorado · Recruiting
Advent Health
Orlando, Florida · Recruiting
Henry Ford Health Cancer
Detroit, Michigan · Recruiting
NYU Langone Health
New York, New York · Recruiting
The University of Texas - MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology, Virginia
Fairfax, Virginia · Recruiting
Swedish Cancer Institute
Seattle, Washington · Recruiting
BC Cancer Vancouver Centre
Vancouver, British Columbia, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Beijing Chest Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.